

Ref. No.: CIAN/BSE/2025-26/27

Tuesday, March 31, 2026

To,  
The Manager-Listing,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400 001

**BSE Scrip Code: 542678**

**Trading Symbol: CHCL**

- Subject:**
- i. Disclosure made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") by Cian Healthcare Limited ("Company"); and
  - ii. Update on the receipt of the Trading approval for the 2,50,00,000 (Two Crores Fifty Lakhs) fully paid-up equity shares, from the BSE Limited ("Stock Exchange" or "BSE") pursuant to the approved Resolution Plan read with the Order of the Hon'ble National Company Law Tribunal ("NCLT") dated December 18, 2025 ("NCLT Order") and further details of which are mentioned hereunder:
    - a. Trading approval for the 12,50,000 (Twelve Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each, to the public shareholder; and
    - b. Trading approval for the 2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each, to the promoters.

**Reference:** Disclosure dated December 19, 2025, in relation to the approval of the Resolution Plan by the Hon'ble NCLT vide its Order dated December 18, 2025, as submitted by the Successful Resolution Applicant ("SRA"), namely Mr. Pradeep Kumar Jain, under the relevant provisions of the Insolvency and Bankruptcy Code, 2016 ("Code").

Dear Sir/Ma'am,

In compliance with the relevant provisions of Regulation 30 read with Schedule III, and other applicable provisions of the Listing Regulations, along with the provisions of SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/11/3762/2026 dated January 30, 2026 ("**SEBI Circular**"), and in accordance with the relevant provisions of the NCLT Order read with the Resolution Plan approved therein and such other applicable laws and regulations,

and with reference to the captioned subject, the Company hereby inform the receipt of the trading approval for the 2,50,00,000 (Two Crores Fifty Lakhs) fully paid-up equity shares, from the Stock Exchange dated March 30, 2026 (received by us on March 30, 2026 at 07:05 p.m. through e-mail), which are enumerated hereunder:

a. **Trading approval for 12,50,000 (Twelve Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each, to the public shareholder; and**

The Company has received the trading approval from BSE for 12,50,000 (Twelve Lakhs Fifty Thousand) fully paid-up equity shares having a face value of INR 10/- (Indian Rupees Ten Only) each, which were allotted to the public shareholders, in the meeting of the Resolution Plan Implementation Committee (CIAN/RPIC/2025-26/04) held on January 23, 2026, in accordance with the provisions of the NCLT Order read with the Resolution Plan approved therein.

b. **Trading approval for 2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each, to the promoters.**

The Company has received the trading approval from BSE for 2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) fully paid-up equity shares having a face value of INR 10/- (Indian Rupees Ten Only) each, which were allotted to the promoters, in the meeting of the Board of Directors (CHL/BM/2025-26/01) held on March 16, 2026, in accordance with the provisions of the NCLT Order read with the Resolution Plan approved therein.

The details in accordance with the provisions of Regulation 30 of the Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (as amended), read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed herewith as **Annexure-A**.

A Copy of the trading approval received from the BSE is enclosed herewith as **Annexure-B**.

We shall continue to keep all stakeholders and regulatory authorities abreast of further material developments in this regard.

Kindly take the above information on record and oblige.

Thanking you,  
**For Cian Healthcare Limited**

\_\_\_\_\_  
**Rachit Malhotra**  
**Company Secretary and Chief Compliance Officer**  
**Membership No.:** A39894  
**Place:** Delhi

### Annexure-A

Relevant details pursuant to Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (as amended) read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr No.	Particulars	Description
a.	Name of the regulatory or licensing authority;	BSE Limited
b.	Brief details of the approval/license obtained/ withdrawn/ surrendered;	<p>Trading Approval for Trading of 2,50,00,000 (Two Crores Fifty Lakhs) fully paid-up equity shares having a face value of INR 10/- (Indian Rupees Ten Only) each, allotted in the following manner:</p> <ul style="list-style-type: none"> <li>12,50,000 (Twelve Lakhs Fifty Thousand) fully paid-up equity shares having a face value of INR 10/- (Indian Rupees Ten Only) each allotted to public shareholders <i>in-lieu</i> of their erstwhile shareholding as on the record date dated January 21, 2026 pursuant to the reduction of the paid-up share capital of such public shareholders, in accordance with the provisions of the NCLT Order read with the resolution plan;</li> </ul> <p>And</p> <ul style="list-style-type: none"> <li>2,37,50,000 (Two Crores Thirty-Seven Lakhs Fifty Thousand) fully paid-up equity shares at a face value of INR 10/- (Indian Rupees Ten Only) each, to the promoters, in accordance with the provisions of the NCLT Order read with the resolution plan.</li> </ul>
c.	Impact/relevance of such approval/license to the listed entity;	Upon receipt of Trading approval for 2,50,00,000 (Two Crores Fifty Lakhs) fully paid-up equity shares having a face value of INR 10/- (Indian Rupees Ten Only) each, the equity shares of the Company are admitted for trading on BSE Limited.
d.	Withdrawal/cancellation or suspension of license/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any;	Not Applicable.

**Registered Office:**

Office No.: 301, 3<sup>rd</sup> Floor, Konark Icon, Mundhwa-Kharadi Road,  
Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra, Pincode-411028.  
Email: enquiry@cian.co  
Mobile No.: +919049000648 Website: [www.cian.co](http://www.cian.co)

**Corporate Office:**

606, Ring Road Mall, Sector-3, Rohini, New Delhi, Pincode-110085.  
Landline No.: 011-49120841

**Factory:** Khasra No.: 245 & 248, Village Sisona, Bhagwanpur,  
Roorkee, District Haridwar, Uttarakhand, Pincode-247661.

Mobile No.: +917830655000

**CIN:** L24233PN2003PLC017563

e.	Period for which such approval/license is/was valid;	Not Applicable
f.	The actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval.	Not Applicable



DCS/AMAL/AK/4144/2025-26

March 30, 2026

To,  
The Company Secretary,  
**Cian Healthcare Ltd**  
606, Ring Road Mall,  
Sector- 3, Rohini,  
Delhi - 110085

Dear Sir/ Madam,

**Subject: Trading Approval for 2,50,00,000 Equity Shares of Rs. 10/- each bearing Distinctive Numbers as 1 to 25000000 pursuant to approved resolution plan as per the Hon'ble NCLT order dated December 18, 2025, of Mumbai Bench under the provisions of Insolvency and Bankruptcy Code, 2016.**

We acknowledge with thanks and have pleasure in advising that effective from April 02, 2026, trading members of the Exchange are allowed to trade in your above-mentioned securities.

Please refer to our Notice No. 20260330-22 dated March 30, 2026, available on our website issued on this behalf to the Trading Members of the Exchange, for your information, the contents of which may please be checked and confirmed by the Exchange.

For BSE Limited,

Yours faithfully,



**Marian Dsouza**  
Assistant Vice President



**Abhishek Kadlak**  
Deputy Manager